Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027
By Kelly Cloonan
Shares of Haemonetics rose after CSL Plasma said it expects to complete the rollout of the company's devices and disposables under their supply agreement by the end of 2027.
The stock gained 16% to $118 in premarket trading Thursday. At Wednesday's market close, shares were up 27% year to date.
Under the supply agreement, which the companies entered in August, CSL can use Haemonetics' NexSys PCS devices and purchase related disposables in the U.S. Haemonetics said at the time the supply agreement was non-exclusive and did not contain minimum purchase commitments.
In a Thursday filing with the Securities and Exchange Commission, Haemonetics said CSL expects the transition to its devices and disposables will occur at all of CSL's current U.S. plasma collection centers.
The scope and timing of the rollout remain subject to change, Haemonetics said, noting it is not updating its previously issued fiscal 2027 guidance at this time.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
October 08, 2026 09:05 ET (13:05 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States